| NK521 in the Treatment of Advanced Solid Tumors (NCT07657416) | Base Therapeutics (Shanghai) Co., Ltd. | 2026-06-01 |
| NK521 in the Treatment of Malignant Ascites Associated With Advanced Solid Tumors (NCT07561437) | Base Therapeutics (Shanghai) Co., Ltd. | 2026-03-09 |
| Safety and Efficacy of NK510 to Treat Gastric Cancer and Colorectal Cancer (NCT07166263) | Base Therapeutics (Shanghai) Co., Ltd. | 2025-11-01 |
| NK510 Cell Therapy for Refractory Systemic Lupus Erythematosus (NCT07083349) | Base Therapeutics (Shanghai) Co., Ltd. | 2025-08-01 |
| Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia (NCT06541405) | Base Therapeutics (Shanghai) Co., Ltd. | 2024-07-01 |
| Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid Leukemia (NCT06541444) | Base Therapeutics (Shanghai) Co., Ltd. | 2024-07-01 |
| Safety and Efficacy of NK510 to Treat Gastric Cancer (NCT06098898) | Base Therapeutics (Shanghai) Co., Ltd. | 2023-11-01 |
| Safety and Efficacy of NK510 to Treat NSCLC (NCT06097962) | Base Therapeutics (Shanghai) Co., Ltd. | 2023-07-01 |
| Safety and Efficacy of NK510 to Treat Osteosarcoma and Soft Tissue Sarcoma (NCT06117878) | Base Therapeutics (Shanghai) Co., Ltd. | 2022-09-01 |